Galapagos Pushes Bone and Joint Compounds Toward Phase I Trials
This article was originally published in The Pink Sheet Daily
New agents could beat standard of care in bone cancer metastases and rheumatoid arthritis, firm says.
You may also be interested in...
Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.
The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.